Skip to content
← Full study record

NCT00025233 · BASELINE

Baseline characteristics

Bevacizumab in Treating Patients With Persistent or Recurrent Cancer of the Cervix · Source last updated 2019-07-24

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms
  1. counts
    1. group Id
      BG000
      value
      46
    units
    Participants
groups
  1. description
    Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
    id
    BG000
    title
    Bevacizumab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.3
          value
          46.4
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      20-29 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      30-39 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      40-49 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      50-59 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      60-69 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          46
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Canada
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Adenosquamous
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          43
      title
      Squamous Cell Carcinoma
    param Type
    NUMBER
    title
    Histologic Type
    unit Of Measure
    participants
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Unspecified
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      Recurrent/Persistent
    param Type
    NUMBER
    title
    International Federation of Gynecology and Obstetrics (FIGO) Stage
    unit Of Measure
    participants
population Description
Eligible and treated patients.
Complete source fields
denoms
  1. counts
    1. group Id
      BG000
      value
      46
    units
    Participants
groups
  1. description
    Bevacizumab 15 mg/kg IV, every 3 weeks (one cycle) until disease progression or adverse effects prohibit further therapy
    id
    BG000
    title
    Bevacizumab
measures
  1. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          spread
          9.3
          value
          46.4
    dispersion Type
    STANDARD_DEVIATION
    param Type
    MEAN
    title
    Age, Continuous
    unit Of Measure
    years
  2. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      20-29 years
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          11
      title
      30-39 years
    3. categories
      1. measurements
        1. group Id
          BG000
          value
          17
      title
      40-49 years
    4. categories
      1. measurements
        1. group Id
          BG000
          value
          12
      title
      50-59 years
    5. categories
      1. measurements
        1. group Id
          BG000
          value
          5
      title
      60-69 years
    param Type
    NUMBER
    title
    Age, Customized
    unit Of Measure
    participants
  3. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          46
        title
        Female
      2. measurements
        1. group Id
          BG000
          value
          0
        title
        Male
    param Type
    COUNT_OF_PARTICIPANTS
    title
    Sex: Female, Male
    unit Of Measure
    Participants
  4. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      United States
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Canada
    param Type
    NUMBER
    title
    Region of Enrollment
    unit Of Measure
    participants
  5. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          3
      title
      Adenosquamous
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          43
      title
      Squamous Cell Carcinoma
    param Type
    NUMBER
    title
    Histologic Type
    unit Of Measure
    participants
  6. classes
    1. categories
      1. measurements
        1. group Id
          BG000
          value
          1
      title
      Unspecified
    2. categories
      1. measurements
        1. group Id
          BG000
          value
          45
      title
      Recurrent/Persistent
    param Type
    NUMBER
    title
    International Federation of Gynecology and Obstetrics (FIGO) Stage
    unit Of Measure
    participants
population Description
Eligible and treated patients.

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice